The Profound Impacts of Precision Medicine, Genomic Sequencing on Cancer Care
Precision Oncology is helping NCI treat cancer based on specific genetic changes in a patient’s tumor by allowing them to target mutations that will lower toxicity and improve overall effectiveness of the treatment.
A clinical trial at the National Cancer Institute called NCI-MATCH showed how cancer patients could benefit from genomic sequencing and is now informing future trials on precision medicine.
The NCI Molecular Analysis for Therapy Choice Trial initially screened 6,000 patients and treated 1,300 of them by pairing certain medications with their specific tumors regardless of the cancer type. Future trials like ComboMATCH will now look at precision medicine to study how tumors respond to targeted treatments.
NCI Researchers Dr. Lindsay Harris and Dr. Peter O’Dwyer shared how precision oncology is expanding treatment options and increasing patients’ survival rates. They also discuss the importance of clinical trials like these for progressing the fight against cancer.
-
Dr. Lyndsay Harris Associate Director, Cancer Diagnosis Program NCI -
Dr. Peter O'Dwyer Group Co-Chair ECOG-ACRIN Cancer Research Group
-
CMS Deploys AI Tools to Improve Security, Privacy
AI-powered tools and bug bounty programs help CMS detect threats and protect sensitive data.
7m watch -
Treating Data as a Utility to Streamline Veteran Services
The agency views its approach to data strategy as a utility to improve veteran services across the enterprise.
4m watch -
The Cybersecurity Nightmares Threatening Modern Organizations
Cybersecurity leaders examine the hidden threats facing organizations, from shadow AI and legacy systems to alert fatigue, analyst burnout and emerging AI risks.
17m watch -
Keeping Aging Federal Systems Running Amid OT Vulnerabilities
A techno-thriller novel highlights how organizational silos can become critical infrastructure vulnerabilities in the AI era.
19m watch